Tempus AI, Inc. - TEM Company Value to Revenue

tempus.com (TEM) - corporate logo

Tempus AI, Inc (TEM) is implementing AI to analyze genomic datasets, establishing a foundation for stable cash flow. The shift in the EV/Sales multiple demonstrates that the current metric is 7730.16. Strict data privacy regulations ensure a high barrier to entry. Meanwhile, dominance in precision medicine driven by unique training algorithms creates a fundamental advantage over new market entrants.

TEM (Tempus) EV/Sales Multiple history from 11/23/2025 to 11/20/2026

Tempus Labs - analytical breakdowns and key metrics (TEM)

- share price and consensus valuation forecast:
Initial company analysis:Tempus Labs, TEM
Manufactured product of Tempus AI Inc

For Tempus AI, Inc (TEM), a leader in AI-driven genomic data analysis, this indicator allows for an assessment of the business's market value relative to its operating revenues. The EV/Sales ratio is calculated as the ratio of enterprise value (market capitalization plus net debt) to revenue, which eliminates the impact of leverage on the chart. This metric's trend helps investors determine whether the premium for the rapid growth of the client base in oncology centers is justified.

Competitor analysis for Tempus AI, Inc

Total Company Value-to-Revenue Ratio qiagen.com QGEN|IONS: EV/Sales Multiple|Repligen Corp - Business Value to Revenue|RNA (Avidity Corp) - EV/Sales Multiple|CRISPR Therapeutics Corp - Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio genedx.com (WGS)|EV/Sales Multiple ultragenyx.com (RARE)|EV/Sales Multiple BEAM (Beam Therapeutics Inc)|Sarepta Therapeutics Inc (SRPT) - Enterprise Value-to-Revenue Multiple|twistbioscience.com - EV/Sales Multiple|10x Genomics, Inc. - Enterprise Value-to-Revenue Coefficient|NTLA (Intellia Corp) - Company Value to Revenue|Company Value to Revenue stoketherapeutics.com|Company Value to Revenue BLFS|Company Value to Revenue Wave Life Sciences Corp (WVE)|EV/Sales Multiple MAZE|Total Company Value-to-Revenue Ratio Sionna Therapeutics Inc|Enterprise Value-to-Revenue Ratio Prime Medicine Corp PRME|tayshagtx.com (TSHA) - Enterprise Value-to-Revenue Multiple|QURE - Enterprise Value-to-Revenue Ratio|MeiraGTx Holdings (MGTX) - Company Value to Revenue|Regenxbio (RGNX) - Enterprise Value-to-Revenue Ratio|SLDB - Total Company Value-to-Revenue Ratio|OCGN (Ocugen Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio PACB|Enterprise Value-to-Revenue Ratio Benitec (BNTC)|Design Therapeutics Inc - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Rocket Pharma RCKT|EV/Sales Multiple 4DMT FDMT|LXEO - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Korro Bio Inc.|EDIT: EV/Sales Multiple|SLN - Total Company Value-to-Revenue Ratio|PRQR (ProQR Therapeutics) - EV/Sales Multiple|codexis.com (CDXS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple SGMO|EV/Sales Multiple Nautilus Biotechnology, Inc. (NAUT)|EV/Sales Multiple MGX (Metagenomi Inc.)|Business Value to Revenue DTIL|Generation Bio Co. - EV/Sales Multiple|BOLD: Enterprise Value-to-Revenue Ratio|XCUR (Exicure, Inc.) - Company Value to Revenue|Company Value to Revenue Ratio IMNN|Enterprise Value-to-Revenue Ratio RXi Pharmaceuticals|mustangbio.com (MBIO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio TransCode (RNAZ)|Bionano Genomics Inc. - Company Value to Revenue Ratio|Applied DNA Sciences - Company Value to Revenue|Total Company Value-to-Revenue Ratio bluebirdbio.com (BLUE)|IPA - Enterprise Value-to-Revenue Ratio|OMGA - EV/Sales Multiple|OMIC (Singular Genomics Systems, Inc.) - Company Value to Revenue|Regulus Therapeutics Inc - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Syros Pharmaceuticals|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple